8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
Feb 12, 2026·SEC
Material company update
Dec 2, 2025·SEC
Benitec Biopharma Inc.(BNTC)Earnings, Financials & Key Ratios
BNTC•NASDAQ
$13.20
Price updated Jul 6, 2026
AboutBenitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.Show more
- Revenue$0
- EBITDA-$41M-86.8%
- Net Income-$38M-74.3%
- EPS (Diluted)-1.05+60.8%
- ROE-52.46%+42.8%
BNTC Price & Volume
Benitec Biopharma Inc. (BNTC) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Revenue Generation Potential
Investment Thesis • Updated 2026Q3
VerdictNeutral
Growth:Contracting
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:Binary clinical trial dependency
Key Thesis Takeaways
- Benitec Biopharma remains a high-risk, development-stage entity with no commercial revenue, relying entirely on its ddRNAi platform to achieve clinical validation.
- While the company maintains a substantial $184.8 million cash position as of 2026Q3, the persistent quarterly operating losses of $13.6 million necessitate ongoing capital efficiency.
- Investors should monitor the binary nature of upcoming clinical readouts, as the current valuation is entirely decoupled from traditional earnings metrics and remains sensitive to potential equity dilution.
Verdict Logic
while the $184.8 million cash balance provides a significant runway, the lack of revenue and consistent quarterly operating losses of $13.6 million suggest that the firm remains highly vulnerable to binary clinical trial outcomes.
BNTC Growth Metrics
Benitec Biopharma Inc. (BNTC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-44.49%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM29.75%
Return on Capital
10 Years-165.05%
5 Years-272.92%
3 Years-374.51%
Last Year-57.58%
BNTC Recent Earnings
Benitec Biopharma Inc. (BNTC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.24+11.1%
$0.27
Rev
—
$5M
Q2 2026
May 13, 2026Metric
Actual
Est
EPS
$0.24+11.1%
$0.27
Rev
—
$5M
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$0.26-13.0%
$0.23
Rev
—
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.22+37.1%
$0.35
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.24vs $0.27+11.1% | —vs $5M |
| Q2 2026 | May 13, 2026 | $0.24vs $0.27+11.1% | —vs $5M |
| Q1 2026 | Feb 12, 2026 | $0.26vs $0.23-13.0% | — |
| Q4 2025 | Nov 14, 2025 | $0.22vs $0.35+37.1% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Benitec Biopharma Inc. (BNTC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.20 | $346.46M | -12.57 | — | — | -52.46% | — | |
| $374.68 | $11.05B | 54.78 | 33.94% | 53.92% | 19.25% | — | |
| $3.99 | $435.68M | -1.99 | — | — | -70.79% | — | |
| $41.36 | $2.59B | -11.95 | -40.64% | -1154.42% | -145.81% | — | |
| $11.07 | $862.47M | -5.56 | — | — | -74.45% | — | |
| $8.24 | $105.7M | -2.27 | -50.12% | -98.7% | -81.24% | — |
Compare BNTC vs Peers
Benitec Biopharma Inc. (BNTC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BNTC SEC Filings & Documents
Benitec Biopharma Inc. (BNTC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when BNTC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BNTC Frequently Asked Questions
Benitec Biopharma Inc. (BNTC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is BNTC profitable?
Benitec Biopharma Inc. (BNTC) reported a net loss of $48.9M for fiscal year 2025.
Dividend & Returns
What is BNTC's return on equity?
Benitec Biopharma Inc. (BNTC) has a return on equity (ROE) of -52.5%. Negative ROE indicates the company is unprofitable.
What is Benitec Biopharma Inc.'s free cash flow?
Benitec Biopharma Inc. (BNTC) had negative free cash flow of $20.6M in fiscal year 2025, likely due to heavy capital investments.